Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
Public ClinicalTrials.gov record NCT07352566. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Utilization of a Cutaneous Therapy In Situ Microdevice
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis. The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.
Study identification
- NCT ID
- NCT07352566
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Interventions
- In situ cutaneous microdevice Device
- Triamcinolone Drug
- 5-Fluorouracil Drug
- Calcipotriene Drug
- Tapinarof Drug
- Crisaborole Drug
- Tacrolimus Drug
- Adalimumab Drug
- Etanercept Drug
- Certolizumab Drug
- Infliximab Drug
- Secukinumab Drug
- Ixekizumab Drug
- Apremilast Drug
- Risankizumab Drug
- Ustekinumab Drug
- Hydroxychloroquine Drug
- Methotrexate Drug
- Mycophenolate Drug
- Azathioprine Drug
- Chloroquine Drug
- Cyclosporine Drug
- Tofacitinib Drug
- Deucravacitinib Drug
- Dupilumab Drug
- Tralokinumab Drug
- Guselkumab Drug
- Tildrakizumab Drug
- Baractinib Drug
- Abrocitinib Drug
- Upadacitinib Drug
- Lebrikizumab Drug
- Nemolizumab Drug
- Ruxolitinib Drug
- Bimekizumab Drug
- Roflumilast Drug
Device · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2026
- Primary completion
- May 31, 2030
- Completion
- May 31, 2030
- Last update posted
- Jun 2, 2026
2026 – 2030
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94158 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07352566, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 2, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07352566 live on ClinicalTrials.gov.